Form 4: Trevi Therapeutics Director Edward Mathers Granted 45,000 Stock Options

Trevi Therapeutics, Inc. director Edward T. Mathers was granted 45,000 nonstatutory stock options with an exercise price of $6.25 per share, as disclosed in a recent SEC Form 4 filing.

Summary

• Edward T. Mathers, a Director of Trevi Therapeutics, Inc. (TRVI), was granted 45,000 nonstatutory stock options.
• The options have an exercise price of $6.25 per share.
• The grant date for these options was June 11, 2025.
• The options are scheduled to expire on June 10, 2035.
• Vesting of the options will occur on the earlier of (i) the first anniversary of the grant date (June 11, 2026) or (ii) the date of the next annual meeting of stockholders following the grant date, subject to continued service.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it reflects continued director commitment and aligns interests with shareholders, but it is a routine disclosure and does not provide new financial performance data.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the options gain value only if the company's stock price increases above the exercise price.
• This indicates continued commitment and service from a key board member.

Future Outlook

The options are structured to vest based on future service, either one year from the grant date or at the next annual stockholders' meeting, indicating an expectation of continued director service and alignment with future company performance.

Industry Context

Stock option grants are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, aiming to incentivize long-term performance and align leadership interests with shareholder value creation.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options become more valuable if the stock price increases.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The options will vest based on the specified conditions (first anniversary of grant or next annual meeting), subject to the director's continued service.
• Upon vesting, the director will have the right to exercise the options to purchase common stock at the stated exercise price.

Key Dates

Keywords

Trevi Therapeutics, TRVI, SEC Form 4, Stock Option Grant, Director Compensation, Insider Transaction, Equity Incentive, Edward Mathers